Please login to the form below

Not currently logged in
Email:
Password:

romosozumab

This page shows the latest romosozumab news and features for those working in and with pharma, biotech and healthcare.

UCB looks to pipeline with five years left for twin blockbusters

UCB looks to pipeline with five years left for twin blockbusters

25%. The first new product to hit the market is osteoporosis candidate Evenity (romosozumab), co-developed and co-marketed with Amgen.  The drug has suffered setbacks in reaching the market, being

Latest news

  • Evenity back on track with FDA panel blessing in osteoporosis Evenity back on track with FDA panel blessing in osteoporosis

    Amgen has already secured its first marketing approval for Evenity (romosozumab) – in Japan earlier this month – and with US approval seemingly assured now has the successor it needs for its $2bn

  • FDA rejects Amgen's osteoporosis hope romosozumab FDA rejects Amgen's osteoporosis hope romosozumab

    The FDA has turned down Amgen's marketing application for osteoporosis candidate romosozumab, asking for new data that could delay any approval significantly. ... The FDA's complete response letter (CRL) does not come out of the blue as Amgen and its

  • CHMP recommends Merck & Co's Lantus biosimilar CHMP recommends Merck & Co's Lantus biosimilar

    competition. Furthermore, Amgen and UCB's rival osteoporosis drug romosozumab has demonstrated superior results to Forteo in phase III trials, and analysts have suggested the emerging anti-sclerostin antibody class will

  • Amgen's Kyprolis scarred by head-to-head duel with Velcade Amgen's Kyprolis scarred by head-to-head duel with Velcade

    Romosozumab filed  . There was some better news for Amgen and partner UCB this week when the FDA started its review of romosozumab, their drug candidate for the treatment of osteoporosis in ... Romosozumab did well in phase III trials - cutting the risk

  • Merck decision to drop odanacatib lifts UCB/Amgen Merck decision to drop odanacatib lifts UCB/Amgen

    Their anti-sclerostin antibody romosozumab is well ahead of other drugs in the emerging class and has been shown to be superior to Eli Lilly's big-selling osteoporosis therapy Forteo ... Deutsche Bank analysts have said they see romosozumab and

More from news
Approximately 6 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Investing in the future of R&D Investing in the future of R&D

    One of UCB's brightest prospects is its osteoporosis candidate romosozumab. In January phase II trial results were published that showed significant increases in low bone mineral density at both spine

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    Providing an example, he explains UCB's use of genetics in its development of romosozumab, currently in phase III investigation in partnership with Amgen for use in the treatment of ... UCB's work on romosozumab with Amgen is also an example of the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics